Immuron Limited (NASDAQ: IMRN) has announced that it has received a European Patent for methods and composition for traveler’s diarrhea treatment. The patent granted on January 2, 2022, is entitled “Composition and method for the treatment and prevention of enteric bacterial infections.”
Medical profession acknowledging post-infectious sequelae
Additionally, the medical profession, as a result of travelers ‘ diarrhea, is increasingly acknowledging post-infectious sequelae, such as post-infectious inflammatory bowel disease and many post-infectious autoimmune illnesses. Therefore, the US Military has set a high priority on developing a prophylactic therapy for gastrointestinal infections.
Greece, France, Sweden, Spain, Germany, Denmark, Austria, Finland, and the UK are European countries where Immuron certifies the patent. Notably, the European certification strengthens Immuron’s patent status in Australia, Canada, India, and the US for compositions and techniques for travelers’ diarrhea treatment.
Infectious diarrhea is perhaps the most prevalent ailment among travelers to underdeveloped nations and US personnel stationed abroad. Diarrhea causes morbidity and discomfort, which reduces everyday performance, impairs judgment, lowers morale, and reduces operational preparedness. Antibiotics are usually prescribed as the first-line treatment for infectious diarrhea. Unfortunately, some intestinal infections have developed resistance to frequently administered antibiotics over the previous decade.
Immuron awarded $3.43 million by US DoD
Recently, the company received a $3.43 million financing from the US Department of Defence for Travelan. The total award of $4.45 million is to evaluate a dosing regimen for Travelan that is suited for the military. The focus of the new agreement titled, “Biologics License Application (BLA) of a therapeutic Bovine Immunoglobulin supplement targeting Travelers’ Diarrhea caused by Enterotoxigenic Escherichia Coli (ETEC),” seeks to confirm the efficacy of single Travelan dose in controlled human infection model clinical study.
CEO Jerry Kanellos said, “This new project expands our clinical development program and represents the first of several significant clinical trials which the Company expects to undertake with the US Military in 2022. The NMRC also plans to clinically evaluate the protective efficacy of our new oral therapeutic targeting Campylobacter and ETEC this year in two controlled human infection-model clinical trials.”
